We may get an update at the annual meeting on Europe. Regarding FDA, they already announced 1st half of June is the meeting date. The 6 weeks is a guideline that is typically missed by the FDA due to scheduling issues of all the needed parties. Also, it may be a good sign that DVAX was able to be comprehensive in their preparation to address CKD and manufacturing issues. 6 weeks would have been super tight, especially with management transition.
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
5/15/2013 21,392,620 1,291,137 16.568823
4/30/2013 22,145,156 1,721,849 12.861265
4/15/2013 22,330,276 2,166,185 10.308573
3/28/2013 21,348,647 1,905,524 11.203557
3/15/2013 19,849,404 3,152,466 6.296469
2/28/2013 17,812,131 7,928,208 2.246678
2/15/2013 19,058,154 2,925,650 6.514161
1/31/2013 18,876,959 1,780,638 10.601233
1/15/2013 19,371,845 2,350,346 8.242125
You may be a bit optimistic about Tuesday. This is likely to dip post reverse split. Congrats if you bought in the 1's, but I think this takes a hit for the first week of trading post split. Then there is the prospect, even likelihood some hedge fund is going to finance an analyst report to whack OTEL on valuation to buy shares on the cheap. Might bottom say a week from Tuesday, then I'll take another gander.
He didn't have to excercise it until after FDA meeting. Obviously by purchasing now, he's quite optimistic about the June meeting.
Not an issue with patent, anyone would have to do a new trial. The filters are not going to be allowed to be produced generically and commercialized without it's own trial. This is one aspect of the FDA panel that will actually help DCTH long term.
That is incorrect. The question #3 asked about GEN 1 further trials related to the Clark filter which was substituted into the trial, replacing the original filter. GEN 2 was not considered at all, not one bit.
I'm guessing you are correct. In a twisted way it benefited existing shareholders to get new suckers in the game at an artificially high price.
It should be less than 2 years with EAP and Compassionate use data
DCTH has to submit trial data for GEN 2, just like every company that has a product approved. So far DCTH has not done that. They will, but it will be some time, hopefully less than 2 years and will cost money.
They are being treated right here in the USA with GEN 2 filter right now at Sky ridge medical center.
I agree, it's madness. I mean it won't even be viable commercially if approved, which it won't. First switching filters mid-trial, now trying to push forward an inferior product. Hobbs needs to be fired, what a screw up!
Easy, GEN 1 is total no go. GEN 2 will not be approved without a new expensive trial in US. Dilution is coming to all shares. Hence price approaches cash as new money is coming in on the cheap.